Literature DB >> 3871240

Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?

I Irwin, J W Langston.   

Abstract

The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is rapidly metabolized to a 1-methyl-4-phenylpyridinium species (MPP+) in the squirrel monkey. After administration of toxic doses of MPTP, the concentration of MPP+ in the substantia nigra appears to increase during the first 72 hours, reaching the highest concentration of any central nervous system (CNS) tissue studied. In contrast, the concentration of this compound in other brain areas suggested time dependent elimination during the same period. Pretreatment of animals with the monoamine oxidase (MAO) inhibitor pargyline blocks both the neurotoxic action and the biotransformation of MPTP. In animals given pargyline and MPTP, initial MPTP levels are much higher in all brain regions than in those not receiving pargyline, but by 12 hours, MPTP levels had fallen rapidly in all regions except the substantia nigra and the eye. It may be that the selective toxicity of MPTP is related in some way to the accumulation of its oxidized metabolite in the substantia nigra.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871240     DOI: 10.1016/0024-3205(85)90060-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Selective decrease of immunoreactive tyrosine hydroxylase in nigrostriatum of adult male rats after N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.

Authors:  L L Vacca-Galloway; R Ikeda; S Y Coleman
Journal:  Cell Tissue Res       Date:  1988-07       Impact factor: 5.249

Review 2.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

3.  Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  S M Efange; R J Boudreau
Journal:  J Comput Aided Mol Des       Date:  1991-10       Impact factor: 3.686

Review 4.  The hypothalamus in MPTP-induced parkinsonism.

Authors:  R Sandyk; R P Iacono; S R Kay
Journal:  Ital J Neurol Sci       Date:  1990-08

5.  The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site.

Authors:  H Russ; U Pindur; H Przuntek
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

6.  MPP(+) -dependent inhibition of Ih reduces spontaneous activity and enhances EPSP summation in nigral dopamine neurons.

Authors:  A Masi; R Narducci; E Landucci; F Moroni; G Mannaioni
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

7.  Paradoxical sleep deprivatory effect of a single low dose of MPTP which did not produce dopaminergic cell loss.

Authors:  K Pungor; A Hajnal; K A Kékesi; G Juhász
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

8.  Alteration of monkey retinal oscillatory potentials after MPTP injection.

Authors:  C Harnois; G Marcotte; P J Bédard
Journal:  Doc Ophthalmol       Date:  1987-12       Impact factor: 2.379

9.  Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain.

Authors:  K Suzuki; Y Mizuno; M Yoshida
Journal:  Neurochem Res       Date:  1990-07       Impact factor: 3.996

10.  The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?

Authors:  I Irwin
Journal:  Pharm Res       Date:  1986-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.